A new oral treatment for male pattern hair loss is on the horizon following successful late-stage clinical trials.
Male pattern hair loss, or androgenetic alopecia, is a very common hereditary and hormonal condition affecting men of any age. From puberty there may be telltale signs of the condition, including noticeable hair loss on top of the head or a receding hairline. Over time, affected follicles shrink completely and stop producing hair.
Due to its prevalence, the market is a awash with all kinds of treatments and ‘miracle’ cures – from pills to ointments – in the hope they will stimulate hair growth.
Into this busy marketplace has entered a newcomer with a non-hormonal drug that has shown some very promising results in phase 3 clinical trials.
Developed by US-based biopharmaceutical firm Veradermics, VDPHL01 is an extended-release minoxidil tablet. If this drug sounds familiar, it’s because it has been in use for decades as a drug for high blood pressure. Doctors noticed that their...